Vaccine Adjuvant Alters Neurological Function in Rat Experiment, Symptoms Identical to Autism
Lourdes Salvador
November 30, 2009
Autism is a neurodevelopmental disability characterized by social withdrawal, communication deficits, and repetitive behaviors. Both genetic and environmental factors have been implicated as causes of autism, moreover a high body burden of mercury and other toxic metals from vaccinations and environmental exposures has been increasingly given more attention.
Thimerosal is mercury containing vaccine preservative added to many childhood vaccines. It is widely suspected as a cause of an increasing widespread epidemic of childhood neurodevelopmental disorders such as autism.
Now, a new study shows that administration of thimerosal leads to long lasting neurological impairment in rats, specifically by altering the neural process of handling noxious stimuli.
Analysis also shows that significant amounts of mercury from thimerosal accumulates in the rat brain and remains long term. The mercury is not readily cleared, as was previously believed. Though mercury readily leaves the blood stream, it does not leave the body. It is now recognized to accumulate in brain tissue.
Additionally, this research is supported by various prior studies which show that children with autism suffer from a weak ability to excrete mercury and that the weaker the ability, the more severe the symptoms of autism.
Now, two new research studies investigating the effects of chelation therapy on the health and behavior of children with autism spectrum disorders have discovered that children receiving chelation to reduce mercury levels had significant improvements.
It appears that mercury may produce they symptom set recognized in the autism spectrum disorders as a form of autism.
References
Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet J, El-Dahr J. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A--medical results. BMC Clin Pharmacol. 2009 Oct 23;9:16.
Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet J, El-Dahr J. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. BMC Clin Pharmacol. 2009 Oct 23;9:17.
Olczak M, Duszczyk M, Mierzejewski P, Majewska MD. Neonatal administration of a vaccine preservative, thimerosal, produces lasting impairment of nociception and apparent activation of opioid system in rats. Brain Res. 2009 Dec 8;1301:143-51. Epub 2009 Sep 9.
This article originally appeared in the MCS America News, December 2009 Issue http://mcs-america.org/december2009.pdf. For more articles on this topic, see: MCSA News.
Copyrighted 2009 Lourdes Salvador & MCS America
Thimerosal is mercury containing vaccine preservative added to many childhood vaccines. It is widely suspected as a cause of an increasing widespread epidemic of childhood neurodevelopmental disorders such as autism.
Now, a new study shows that administration of thimerosal leads to long lasting neurological impairment in rats, specifically by altering the neural process of handling noxious stimuli.
Analysis also shows that significant amounts of mercury from thimerosal accumulates in the rat brain and remains long term. The mercury is not readily cleared, as was previously believed. Though mercury readily leaves the blood stream, it does not leave the body. It is now recognized to accumulate in brain tissue.
Additionally, this research is supported by various prior studies which show that children with autism suffer from a weak ability to excrete mercury and that the weaker the ability, the more severe the symptoms of autism.
Now, two new research studies investigating the effects of chelation therapy on the health and behavior of children with autism spectrum disorders have discovered that children receiving chelation to reduce mercury levels had significant improvements.
It appears that mercury may produce they symptom set recognized in the autism spectrum disorders as a form of autism.
References
Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet J, El-Dahr J. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A--medical results. BMC Clin Pharmacol. 2009 Oct 23;9:16.
Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet J, El-Dahr J. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. BMC Clin Pharmacol. 2009 Oct 23;9:17.
Olczak M, Duszczyk M, Mierzejewski P, Majewska MD. Neonatal administration of a vaccine preservative, thimerosal, produces lasting impairment of nociception and apparent activation of opioid system in rats. Brain Res. 2009 Dec 8;1301:143-51. Epub 2009 Sep 9.
This article originally appeared in the MCS America News, December 2009 Issue http://mcs-america.org/december2009.pdf. For more articles on this topic, see: MCSA News.
Copyrighted 2009 Lourdes Salvador & MCS America
Print
Email
